Metraipolis › archive › dc_a54b2dd9bf5f

Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41933889
DOI
10.1111/jocd.70821
License (as archived)
solo-consultazione
Archived
2026-11-03T13:00:23.195Z
SHA-256 of the archived text
c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9
Stable URL of this page
https://metraipolis.com/documento/dc_a54b2dd9bf5f

How to cite

Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889 — Europe PMC (en), https://europepmc.org/article/MED/41933889 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a54b2dd9bf5f (Metraipolis archive dc_a54b2dd9bf5f, sha256 c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9)
BibTeX
@misc{dca54b2dd9bf5f,
  title = {Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study — Europe PMC PMID:41933889},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41933889},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a54b2dd9bf5f; sha256 c0371134de2e9c2163e95689dae6b50ef8f9a10a5fb283a6c3aec39a350569c9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41933889. Agents can read the archived copy with the MCP tool read_document.